AstraZeneca: FDA Grants Orphan Drug Designation To Eplontersen For Transthyretin Amyloidosis

AstraZeneca (AZN.L,AZN) reported that Eplontersen has been granted Orphan Drug Designation in the US for the treatment of transthyretin-mediated amyloidosis. Eplontersen is a ligand-conjugated antisense investigational medicine currently in phase III clinical trials for amyloid transthyretin cardiomyopathy and amyloid
transthyretin polyneuropathy.

eplontersen will be jointly developed and commercialized by Ionis and AstraZeneca in the US. Hereditary ATTR-PN is expected to be the first indication for which the
companies will seek regulatory approval for eplontersen, with the potential to
file a new drug application with the FDA by the end of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT